TF Capital

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

UniXell Biotechnology is a developer of cell therapies utilizing human pluripotent stem cell technology. The company focuses on addressing unmet medical needs in neurodegenerative diseases, rare diseases, and tumors. UniXell has established multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology, and high-precision gene editing. These innovations enable the development of effective treatment solutions aimed at improving the lives of patients suffering from complex medical conditions. The company's proprietary intellectual property encompasses various aspects of stem cell preparation, cultivation, differentiation, and gene editing, positioning it as a leader in the advancement of cellular therapies.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

ChemSemi develops 5G chips and semiconductor technologies.

Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer and stem cell therapies for degenerative diseases, particularly in Greater China. The company utilizes proprietary cell-based technologies to create treatments, including various forms of CAR-T therapies targeting different cancer types, such as CD20 for anti-tumor activities, CD22 for B cell malignancies, and therapies aimed at refractory multiple myeloma. Additionally, the company develops NKG2D CAR therapies and treatments for hepatocellular carcinoma, alongside knee osteoarthritis therapies currently undergoing clinical trials. Beyond its therapeutic development, Cellular Biomedicine Group is involved in biopharmaceutical activities encompassing research and development, technical support, and the manufacturing of pharmaceutical products and medical devices. It also operates under a collaboration agreement with Novartis Pharma AG to manufacture and supply the CAR-T cell therapy Kymriah in China. Established in 2001, the company integrates over thirty years of research and clinical experience in cellular medicine, drawing on expertise from collaborations among scientists and medical professionals across the United States, England, and China.

Coordination Pharmaceuticals is a drug development company that aims to address unmet medical needs and improve patient care. The NCP platform was pioneered by the lab of Professor Wenbin Lin at the University of Chicago. As a versatile technology platform, NCP components can be purposefully chosen to synergize with and enhance currently existing therapies. CPI products are especially potent in combination with checkpoint blockade inhibitors by increasing T cell infiltration into lowly immunogenic solid tumors.

CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.

Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting oncology, metabolic diseases, and autoimmune diseases. Utilizing its proprietary CARD (Computer Accelerated Rational Discovery) platform, Regor integrates various scientific disciplines, including structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. This approach allows the company to efficiently produce both best-in-class and first-in-class therapeutic molecules. With a strong emphasis on scientific expertise, Regor Therapeutics aims to deliver clinically differentiated treatments that address unmet medical needs.

QL Biopharma is engaged in the development of innovative and premium me-too drugs specifically aimed at treating chronic metabolic diseases. The company specializes in recombinant protein drugs that target conditions such as diabetes, obesity, and non-alcoholic fatty liver disease. By focusing on these therapeutic areas, QL Biopharma aims to enhance the quality of life for patients suffering from these prevalent health issues.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company focuses on researching and creating breakthrough therapies aimed at treating conditions affecting bones, muscles, and joints. By prioritizing the development of novel drugs, Angitia Biopharmaceuticals aims to improve patient outcomes and facilitate recovery from severe musculoskeletal ailments.

Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices, focusing on innovative solutions for heart valve diseases. Its primary product, Valve Clamp, is an interventional device designed for minimally invasive treatment of mitral valve regurgitation. This device facilitates the closure of heart valves during operations, allowing surgeons to perform heart surgeries with reduced invasiveness. Hanyu Medical's commitment to advancing medical technology positions it as a significant player in the cardiovascular device market.

Ranok Therapeutics is a biotechnology company focused on developing targeted protein degradation technology to discover and create new therapeutics. This innovative approach engages various biological processes and demonstrates superiority over existing targeted protein degradation methods. The company's pipeline includes both well-established and novel drug targets associated with cancer and other diseases that present significant unmet medical needs. Ranok is committed to advancing the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Oceanus Plus is a China-based company dedicated to the development of clinical trial management systems and clinical research products. The company holds independent intellectual property rights, allowing it to create innovative solutions tailored for the clinical research industry. By focusing on these areas, Oceanus Plus aims to enhance the efficiency and effectiveness of clinical trials, contributing to advancements in medical research and healthcare outcomes.

EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.

Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology (CLIA) systems, including advanced point-of-care testing (POCT) systems and molecular diagnostic solutions. Tisenc operates from a facility covering over 16,000 square meters, which houses research and development laboratories, a GMP-certified factory, and an instrument manufacturing facility. The company holds full intellectual property rights for its products and technologies, allowing for complete independence in research, development, and production. Tisenc's innovative technologies support medical practitioners by providing reliable diagnostic reagents and automatic chemiluminescent analyzers, contributing significantly to the field of medical diagnostics.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company specializing in the research and development of innovative biotherapeutics, particularly in the field of anti-tumor therapies. Founded in August 2013 in Suzhou Industrial Park, the company has established a world-class bio-conjugation technology platform that utilizes a ligase-dependent conjugation method. This advanced technology significantly enhances the therapeutic window for developing a series of next-generation Antibody-Drug-Conjugates (ADCs). GeneQuantum is actively working on advancing its ADC candidates towards Investigational New Drug (IND) applications in both the United States and China, while also focusing on expanding its product pipeline to address unmet medical needs in cancer treatment.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.

GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative molecular pharmaceuticals and antibody drugs that target various cancer systems. GenFleet's work involves developing signal transduction regulators, tumor microenvironment modulators, and transcription factors, among other therapeutic agents. The company's mission is to provide effective medical solutions that can reactivate tumor-specific immune responses and enhance the body's own immune system in combating cancer. With a commitment to advancing cancer therapies, GenFleet serves both domestic and international markets.

Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.

Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolism and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, aiming to create immunological pharmaceuticals at the molecular level to address complex chronic conditions such as obesity and diabetes. Through its innovative approach, Eccogene is building a pipeline of metabolic drugs designed to enhance patient outcomes and improve health conditions related to these chronic diseases.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.

Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology (CLIA) systems, including advanced point-of-care testing (POCT) systems and molecular diagnostic solutions. Tisenc operates from a facility covering over 16,000 square meters, which houses research and development laboratories, a GMP-certified factory, and an instrument manufacturing facility. The company holds full intellectual property rights for its products and technologies, allowing for complete independence in research, development, and production. Tisenc's innovative technologies support medical practitioners by providing reliable diagnostic reagents and automatic chemiluminescent analyzers, contributing significantly to the field of medical diagnostics.

Xpect Vision, founded in 2015, is a high-tech company specializing in the development of innovative medical imaging technologies. The company focuses on photon-counting X-ray imaging and is advancing the field with the creation of high-speed, high-definition imaging chips. Xpect Vision manufactures imaging chips that utilize digital X-ray imaging technology and CMOS X-ray detection methods, which are designed to enhance medical detection services. These products aim to improve the accuracy of cancer diagnoses, enabling physicians to deliver more efficient and effective healthcare solutions. Through its commitment to disruptive technology development, Xpect Vision is positioning itself as a leader in the future of imaging technology.

Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

TongliBio is focused on developing innovative and affordable medical products to address unmet medical needs, particularly in the realm of tropical diseases. The company engages in discovering new drugs and advancing translational medicine, conducting pioneering preclinical and clinical research on anti-infectious agents. Additionally, TongliBio employs proprietary chemoenzymatic process technology to promote green manufacturing practices in pharmaceuticals. Through these efforts, the company aims to provide quality medical solutions for infectious diseases.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company specializing in the research and development of innovative biotherapeutics, particularly in the field of anti-tumor therapies. Founded in August 2013 in Suzhou Industrial Park, the company has established a world-class bio-conjugation technology platform that utilizes a ligase-dependent conjugation method. This advanced technology significantly enhances the therapeutic window for developing a series of next-generation Antibody-Drug-Conjugates (ADCs). GeneQuantum is actively working on advancing its ADC candidates towards Investigational New Drug (IND) applications in both the United States and China, while also focusing on expanding its product pipeline to address unmet medical needs in cancer treatment.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010, headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris is committed to advancing therapeutic solutions that integrate both diagnosis and treatment, catering to the needs of patients in China and globally. Through its innovative approach, the company seeks to contribute significantly to the fields of oncology and infectious disease management.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Wecare Probiotics is a national high-tech enterprise focused on the research and development, production, and application of probiotic strains. The company offers a diverse range of probiotic products, including fermented food strains and beneficial microbial flora, suitable for various industries such as food, healthcare, and medicine. By prioritizing quality and efficiency, Wecare Probiotics aims to deliver effective solutions that meet the needs of its customers.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Shanghai Sanyou Medical Co., Ltd specializes in the research and development, manufacturing, and sales of innovative orthopedic implants and medical devices. The company is located in the Medical Apparatus Garden of Zhangjiang Hi-Tech Park in Shanghai. Its product range includes type III implantation equipment for orthopedics, type III intracranial hematoma puncture removal equipment, as well as various types of surgical instruments and nursing materials. Since its restructuring in September 2010, the company has aimed to establish a sustainable and valuable presence in the medical device industry.